HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).

EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.

Interview Questions:

1. What is the reasoning for this study?
2. Could you tell us about the mechanism of action for mavacamten?
3. What was the study design and patient population?
4. What are the key findings?
5. How will these findings inform future research into mavacamten and HFpEF?

Recorded remotely from Chicago, 2024.

Editor: Jordan Rance
Video Specialist: David Ben-Harosh